Table 2 Transplant-related outcomes with... | American Society of Hematology

Table 2

Transplant-related outcomes with RIC conditioning

Reference	No. of patients	Graft	T-cell depletion	GVHD prophylaxis	Graft failure (%)	aGVHD grade 2 to 4 (%)	aGVHD grade 3 to 4 (%)	cGVHD (%)
MMURD
50	59	PBSC	Alemtuzumab	CSA, MMF	3	69	26	41
51	45	PBSC		TAC, MTX, bortezomib	4	22	7	29
Haploidentical
35	49	PBSC	Alemtuzumab	CSA, MMF	6	16	8	14
52	26	PBSC	ATG	TAC, steroid	4	40	NR	25
53	61	PBSC	OKT-3, TCD	MMF	8	46	NR	18
86	83	PBSC	ATG	CSA, MTX	5	20	7	34
54	66	PBSC	ATG	TAC, steroid	6	NR	8	33
55	33	BM + PBSC	ATG	CSA, MMF, anti-CD25	0	9	6	31
77	33	PB	ATG	TAC, MMF, CY	NR	20	NR	7
77	32	BM		TAC, MMF, CY	NR	11	NR	18
78	28	BM		CNI, MMF	NR	43	11	35
38	68	BM		TAC, MMF, CY	13	34	6	25
40	50	BM		TAC, MMF, CY	2	32	0	13
56	53	60% BM		TAC, MMF	2	30	11	38
UCB
22	64	Double	ATG	TAC based	NR	14	3	22
19	32	Double	ATG	Sirolimus, TAC	9	9	3	13
91	65	Double	ATG	CSA, MMF	NR	57	25	19
41	43	Double	ATG	CSA, MMF	11	49	NR	17
39	110	Double	ATG	CSA, MMF	6	59	22	23
21	21	Double	ATG	CSA, MMF	10	40	5	31
57	104	75% Single	46% ATG	CSA based	NR	24	8	18
40	50	Double		CNI, MMF	12	40	21	25
83	30	Single		CSA	7	27	23	23
90	1072	Single		NR	NR	46	NR	28
15	119	Single or double		CSA, MMF	NR	47 (RIC); 67 (MA)	16 (RIC); 31 (MA)	30 (RIC); 34 (MA)

Reference	No. of patients	Graft	T-cell depletion	GVHD prophylaxis	Graft failure (%)	aGVHD grade 2 to 4 (%)	aGVHD grade 3 to 4 (%)	cGVHD (%)
MMURD
50	59	PBSC	Alemtuzumab	CSA, MMF	3	69	26	41
51	45	PBSC		TAC, MTX, bortezomib	4	22	7	29
Haploidentical
35	49	PBSC	Alemtuzumab	CSA, MMF	6	16	8	14
52	26	PBSC	ATG	TAC, steroid	4	40	NR	25
53	61	PBSC	OKT-3, TCD	MMF	8	46	NR	18
86	83	PBSC	ATG	CSA, MTX	5	20	7	34
54	66	PBSC	ATG	TAC, steroid	6	NR	8	33
55	33	BM + PBSC	ATG	CSA, MMF, anti-CD25	0	9	6	31
77	33	PB	ATG	TAC, MMF, CY	NR	20	NR	7
77	32	BM		TAC, MMF, CY	NR	11	NR	18
78	28	BM		CNI, MMF	NR	43	11	35
38	68	BM		TAC, MMF, CY	13	34	6	25
40	50	BM		TAC, MMF, CY	2	32	0	13
56	53	60% BM		TAC, MMF	2	30	11	38
UCB
22	64	Double	ATG	TAC based	NR	14	3	22
19	32	Double	ATG	Sirolimus, TAC	9	9	3	13
91	65	Double	ATG	CSA, MMF	NR	57	25	19
41	43	Double	ATG	CSA, MMF	11	49	NR	17
39	110	Double	ATG	CSA, MMF	6	59	22	23
21	21	Double	ATG	CSA, MMF	10	40	5	31
57	104	75% Single	46% ATG	CSA based	NR	24	8	18
40	50	Double		CNI, MMF	12	40	21	25
83	30	Single		CSA	7	27	23	23
90	1072	Single		NR	NR	46	NR	28
15	119	Single or double		CSA, MMF	NR	47 (RIC); 67 (MA)	16 (RIC); 31 (MA)	30 (RIC); 34 (MA)

OKT-3, monoclonal anti-CD3 antibody.